In short
REGN17372 is an investigational protein-based substance with no marketing authorisation, supplied by Regeneron Pharmaceuticals, Inc. It is being studied in one authorised Phase 1 clinical trial in combination with linvoseltamab for adults with relapsed/refractory multiple myeloma (RRMM). The trial plans to enrol 99 participants and is currently authorised but not yet recruiting.
Key points
- REGN17372 is an investigational protein-based substance with no marketing authorisation.
- It is being tested in relapsed/refractory multiple myeloma in one authorised Phase 1 trial.
- The trial combines REGN17372 with linvoseltamab and plans to enrol 99 participants.
- The study measures dose-limiting toxicities and response rates such as very good partial response (VGPR).
- REGN17372 is given as a powder for solution for infusion by intravenous use.
What is REGN17372?
REGN17372 is an investigational protein-based substance, meaning it is a biological medicine made from proteins rather than a chemically synthesised small molecule. It has no marketing authorisation in the product records and is therefore not an approved medicine. The substance is supplied by Regeneron Pharmaceuticals, Inc. and appears in one clinical trial as the test substance.
How does REGN17372 work?
The available trial record does not describe the molecular target or mechanism of action of REGN17372. It is being studied in combination with linvoseltamab, another investigational medicine for multiple myeloma, but the source data does not state how REGN17372 itself acts.
Which conditions is REGN17372 studied for?
- Relapsed/refractory multiple myeloma — a cancer of plasma cells in the bone marrow that has come back after treatment (relapsed) or did not respond to previous treatment (refractory).
How is REGN17372 given?
REGN17372 is prepared as a powder for solution for infusion and is given by intravenous use, meaning it is infused directly into a vein. The trial also includes supportive medicines given by mouth or intravenously, such as paracetamol, diphenhydramine and dexamethasone.
What do the clinical trials show?
One authorised Phase 1 trial (EU CT number 2025-522776-93-00) is studying REGN17372 in combination with linvoseltamab in adults with relapsed/refractory multiple myeloma. The trial plans to enrol 99 participants. Phase 1 of the study evaluates safety and tolerability and aims to determine the recommended Phase 2 dose (RP2D) of the combination. Phase 2 of the study will assess preliminary anti-tumour activity of the combination and of linvoseltamab given alone. The main measures include the occurrence and severity of dose-limiting toxicities (DLTs) and treatment-emergent adverse events, as well as response rates such as very good partial response (VGPR) or better and partial response (PR) or better, assessed using International Myeloma Working Group (IMWG) criteria.
What side effects are known?
The trial record does not report side effects of REGN17372. The study is designed to collect information on treatment-emergent adverse events and dose-limiting toxicities, but no results are available yet.